10th Dec 2018 11:10
LONDON (Alliance News) - PureTech Health PLC said Monday its affiliate Vedanta Biosciences has agreed a clinical collaboration with US pharmaceutical giant Bristol-Myers Squibb Co.
The collaboration will evaluate Vedanta's VE800, a microbiome-derived immuno-oncology candidate, with Bristol Myers-Squibb's programmed death-1 immune checkpoint inhibitor, Opdivo, in patients with advanced or metastatic cancers.
Vedanta will maintain control of its VE800 programme, including global research & development and commercial rights.
PureTech said Bristol-Myers Squibb intends to make an equity investment in Vedanta, as part of the collaboration.
"There is growing evidence to support the role of the microbiome across a range of immune-mediated diseases, including cancers. We are pleased to be working with Bristol-Myers Squibb to explore VE800 in combination with Opdivo as a potential treatment option for patients with advanced or metastatic cancers," said PureTech President & Chief of Business & Strategy Bharatt Chowrira.
Shares in PureTech Health were up 3.2% Monday at 185.72 pence each.
Related Shares:
PureTech